**DOCKET NO.:** DM-6964C (BMS-2595)

**Application No.:** 10/786,992

Office Action Dated: January 18, 2006

PATENT REPLY FILED UNDER EXPEDITED PROCEDURE PURSUANT TO 37 CFR § 1.116

This listing of claims will replace all prior versions, and listings, of claims in the application. Listing of Claims:

- 1-9. Canceled.
- 10. (Currently amended) A compound of formula (VI):

$$R^2$$

$$(VI);$$

wherein:

r is an integer from 0 to 4;

R<sup>1</sup> is independently selected at each occurrence from the group consisting of:

C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>2</sub>-C<sub>10</sub> alkenyl, C<sub>2</sub>-C<sub>10</sub> alkynyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl, C<sub>4</sub>-

C<sub>12</sub> cycloalkylalkyl, -NR<sup>1c</sup>R<sup>1d</sup>, -OR<sup>1e</sup>, and -SR<sup>1e</sup>;

 $R^{\mbox{1c}}$  and  $R^{\mbox{1d}}$  are independently selected at each occurrence from the group consisting of:

H,  $C_1$ - $C_{10}$  alkyl,  $C_2$ - $C_{10}$  alkenyl,  $C_2$ - $C_{10}$  alkynyl,  $C_3$ - $C_6$  cycloalkyl and  $C_4$ -

C<sub>12</sub> cycloalkylalkyl;

alternatively,  $R^{1c}$  and  $R^{1d}$  are taken together to form a heterocyclic ring selected from the group consisting of:

piperidine, pyrrolidine, piperazine, N-methylpiperazine, morpholine and thiomorpholine, each heterocyclic ring optionally substituted with 1-3 C<sub>1</sub>-C<sub>4</sub> alkyl groups;

R<sup>1e</sup> is independently selected at each occurrence from the group consisting of:

 $H,\,C_1\text{-}C_{10}\text{ alkyl},\,C_3\text{-}C_6\text{ cycloalkyl},\,\text{and}\,\,C_4\text{-}C_6\text{ cycloalkylalkyl};$ 

 $R^2$  is selected from the group consisting of:

H, C<sub>2</sub>-C<sub>4</sub> alkenyl, C<sub>2</sub>-C<sub>4</sub> alkynyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl, C<sub>4</sub>-C<sub>10</sub> cycloalkylalkyl, C<sub>1</sub>-C<sub>4</sub> hydroxyalkyl, C<sub>1</sub>-C<sub>4</sub> haloalkyl, and C<sub>1</sub>-C<sub>4</sub> alkyl substituted with 0-5 R<sup>2a</sup>;

R<sup>2a</sup> is independently selected at each occurrence from the group consisting of:

**DOCKET NO.:** DM-6964C (BMS-2595)

**Application No.:** 10/786,992

Office Action Dated: January 18, 2006

PATENT REPLY FILED UNDER EXPEDITED PROCEDURE PURSUANT TO 37 CFR § 1.116

H, C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>2</sub>-C<sub>10</sub> alkenyl, C<sub>2</sub>-C<sub>10</sub> alkynyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl, C<sub>4</sub>-C<sub>12</sub> cycloalkylalkyl, halo, CN, C<sub>1</sub>-C<sub>4</sub> haloalkyl, -OR<sup>2e</sup>, and -SR<sup>2e</sup>; and R<sup>2e</sup> is independently selected at each occurrence from the group consisting of:

H, C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl, and C<sub>4</sub>-C<sub>6</sub> cycloalkylalkyl; with the following provisos:

- (1) when R<sup>2</sup> is H, methyl or ethyl, then r is an integer from 1 to 4; and
- (2) when  $R^2$  is unsubstituted  $C_1$ - $C_4$  alkyl, then  $R^1$  is not OH.
- 11. Canceled
- 12. Canceled
- 13. (Previously Presented) A compound according to claim 10 that is selected from the group consisting of:
  - 4-(4-methoxy-2-methyl)phenyl-5-methylisoxazole; and
  - 4-(2,5-dimethyl-4-methoxy)phenyl-5-methylisoxazole.
- 14. (Previously Presented) A compound according to claim 13 that is 4-(2,5-dimethyl-4-methoxy)phenyl-5-methylisoxazole.